GlassScriptPhysician profile
Rafael Rodriguez Lopez
NPI 1275530743
$20,403.96
in general payments reported to CMS, 2019-2025
14 companies · $518 in 2025
The $518 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $720 · 2020: $92.44 · 2021: $523 · 2022: $3,095 · 2023: $9,240 · 2024: $6,215 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,788 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,640 · Food and Beverage: $1,803 · Travel and Lodging: $743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,787.90 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,640.00 |
| Food and Beverage | $1,802.70 |
| Travel and Lodging | $742.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Latin America, INC. | $16,275.43 | 2019-2025 | Evis Exera Lll Colonovideoscope, Evis Exera III Duodenovideoscope, Evis Exera III Colonovideoscope |
| Abbvie INC. | $1,946.34 | 2019-2025 | Mavyret, Skyrizi |
| Olympus Corporation of The Americas | $778.45 | 2023 | Visiglide, Evis Exera Lll Colonovideoscope |
| E.R. Squibb & Sons, L.L.C. | $405.63 | 2021-2025 | Zeposia |
| Boston Scientific Corporation | $262.59 | 2023-2024 | Spyglass Discover, Spyglass |
| Pbg Puerto Rico LLC | $144.22 | 2021-2025 | |
| Gilead Sciences, INC. | $131.80 | 2022-2025 | |
| Pfizer Pharmaceuticals LLC | $111.37 | 2019 | |
| Madrigal Pharmaceuticals | $101.76 | 2025 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.49 | 2024 | Jardiance |
| Ferring Pharmaceuticals INC. | $89.27 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $27.08 | 2024 | |
| Merck Sharp & Dohme LLC | $21.67 | 2025 | Capvaxive |
| Pfizer INC. | $7.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Rodriguez Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.